Zuclopenthixol - Schizophrenia and other psychoses
You are here : Home > Formulary Search > Zuclopenthixol - Schizophrenia and other psychoses
Status 1
- Tablets
Initiation by a SABP specialist and stabilisation for a minimum of 3 months before any request to transfer prescribing responsibility.
Status 2
- Depot injection
Zuclopenthixol decanoate - under the LCS agreement once being prescribed in Primary Care.
Status 3
- Oral drops
In-patient administration only (SABP).
Documentation
- No records returned.
PAD Profile
Other Indications
Below are listed other indications that Zuclopenthixol is used to treat.
- No records returned.
Other Drugs
Below are listed other drugs that are used to treat Schizophrenia and other psychoses.
Committee Recommendations (2)
Follow link to Shared Care Principles and Communication letters Shared Care principles and Communication letters
The Surrey Heartlands APC recommends the administration of depot antipsychotic injections under an AMBER shared care agreement for practices that have signed up to the agreed locally commissioned service (LCS).
The updated shared care agreement can be found below.
Surrey Heartlands CCG have developed the LCS to enable stable patients with schizophrenia to be prescribed and administered these injections through their primary care prescriber (GP).
If a practice has not signed up to the LCS the drug remains as RED status and prescriptions will be issued by the provider.
Note: Clopixol Acuphase is an intermediate-acting formulation of zuclopenthixol acetate which should only be used on in-patient units for the short-term management of acute psychotic episodes and mania. When prescribing intramuscular zuclopenthixol, check that the prescription is clear and unambiguous in order to ensure the intended treatment is dispensed and administered